Loading…
← CockpitCompetitor Analysis › 688247.SS Sinotherapeutics, Inc. Class AOpen in the cockpit ↗

Sinotherapeutics, Inc. Class A688247.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum weak 35
Mkt cap
$494M
US dollars, full cap
Free float
21%
of shares outstanding
$/day
$6.15M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-1.8 pp
WACC 5.6%
Hurdle
+22 pp
Req g minus delivered
Close · CNYCN¥7.42
1D-1.5%
1W-8.1%
1M-16.0%
3M-26.5%
6M-19.3%
YTD-23.5%
1Y-31.7%
ATR %5.4%
52w lowhigh35.2% off high

What Sinotherapeutics does

Employees: 319

Sinotherapeutics at a glance

Size Sinotherapeutics (688247.SS) is a China Health Care company (Biotechnology) with a market value of $494M, the 3724th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.42 on 18 Nov 2026.

Performance Over six months the shares fell 19.3%, against -5.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 18 in its peer set.

Growth Revenue fell 17.2% over the last twelve months (peer median -1.5%); the operating margin is -0.2% (peer median -13.1%).

Valuation It trades at 6.2× enterprise value to sales against a peer median of 7.5× (6th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.8 points below its cost of capital (5.6% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 90688247.SS 82
Six months, rebased to 100: Sinotherapeutics against the median of its 20 peers (local-currency closes).

Sinotherapeutics financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥398MCN¥446MCN¥511MCN¥300MCN¥248M
Revenue growth—-13%+71%+21%—
Gross profitCN¥168MCN¥159MCN¥251MCN¥154MCN¥158M
EBITDAn/aCN¥66.7MCN¥144MCN¥66.7MCN¥85.3M
Net incomeCN¥18.1MCN¥47.5MCN¥128MCN¥61.1MCN¥92.9M
Free cash flowCN¥88.7MCN¥63.4MCN¥46.3M-CN¥10.2M-CN¥96.3M
Capital expenditureCN¥26.2MCN¥41.6MCN¥94.9MCN¥39.0MCN¥176M
Total debtCN¥38,667CN¥22,551CN¥6,393CN¥85,103CN¥1.52M

Quarterly statements and history in the cockpit →

Sinotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%6032556586300858VLA4147MNPRFENCDMACSTTK0419601151801521688247.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sinotherapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×2,500×5,000×7,500×6032556586300858VLA4147FENC041960115180688247.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sinotherapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%+200%0%100%200%FENCKMDA1521688247.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sinotherapeutics is the large dot.

Sinotherapeutics competitors and peer comparison

How Sinotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sinotherapeutics against its 20 peers (data as of 18 Nov 2026)
Measure688247.SSPeer medianRank in peer set
1-month return-16.0%-10.2%8th lowest of 21
6-month return-19.3%-5.6%7th lowest of 18
Distance from 52-week high-35.2%-46.1%7th highest of 21
Revenue growth (TTM)-17.2%-1.5%5th lowest of 14
Operating margin-0.2%-13.1%6th highest of 14
EV / Sales6.2×7.5×6th cheapest of 14
Growth the price implies (Req g, 7 yrs)29.4%14.3%2nd most demanding of 4
Growth delivered (Del g)+7.0%+15.4%2nd lowest of 4
Hurdle (Req g minus delivered)+22.4 pp-1.5 ppmost demanding of 4
ROIC minus cost of capital-1.8 pp-5.7 pp2nd highest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a

Questions

Which companies are Sinotherapeutics's closest peers?
The cockpit's peer set: Liaoning Dingjide Petrochemical (603255.SS), CHO Pharma (6586.TWO), Beijing Scitop Bio-Tech (300858.SZ), Crescent Biopharma (CBIO), Valneva (VLA.PA), TaiMed Biologics (4147.TWO), Monopar Therapeutics (MNPR), Neurogene (NGNE).
Is Sinotherapeutics expensive compared with its peers?
On ev / sales it trades at 6.2× against a peer median of 7.5×, 6th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sinotherapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -19.3% against -5.6% for the median peer; over one year -31.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.